Burosumab Versus Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Sub-group Analysis by Dose Level.
Erik Allen ImelFrancis H GlorieuxMichael P WhyteAnthony A PortaleCraig F MunnsOla NilssonJill H SimmonsRaja PadidelaNoriyuki NambaHae Il CheongPisit PitukcheewanontEtienne SochettWolfgang HöglerKoji MuroyaHiroyuki TanakaGary S GottesmanAndrew BigginFarzana PerwadAngel ChenMary Scott RobertsLeanne M WardPublished in: The Journal of clinical endocrinology and metabolism (2023)
Prior phosphate or active vitamin D doses did not influence treatment response after switching to burosumab among children with XLH and active radiographic rickets. Switching from conventional therapy to burosumab improved rickets and serum alkaline phosphatase more than continuing either higher or lower doses of phosphate or active vitamin D.